Table 3.
Prevalence of hepatitis B virus serum markers and DNA in 2770 patients n (%)
| No. | HBsAg+ | HBsAb+ | HBeAg+ | HBeAb+ | Isolated HBcAb+ | HBV-sm positive1 | Screening HBV DNA2 | |
| Total | 2770 | 372 (13.4) | 1367 (49.4) | 43 (1.6) | 600 (21.7) | 284 (10.3) | 656 (23.7) | 177 (27.0) |
| Age (yr) | ||||||||
| ≤ 20 | 27 | 2 (7.4) | 14 (51.9) | 1 (3.7) | 2 (7.4) | 1 (3.7) | 3 (11.1) | 1 (33.3) |
| >20 | 2743 | 370 (13.5) | 1353 (49.3) | 42 (1.5) | 598 (21.8) | 283 (10.3) | 653 (23.8) | 176 (27.0) |
| Sex | ||||||||
| Women | 1495 | 144 (9.6) | 780 (52.2) | 15 (1.0) | 280 (18.7) | 146 (9.8) | 290 (19.4) | 52 (17.9) |
| Men | 1275 | 228 (17.9) | 587 (46.7 | 28 (2.2) | 320 (25.5) | 138 (10.8) | 366 (28.7) | 125 (34.2) |
| Types of tumor | ||||||||
| Hematological | 134 | 21 (15.7) | 51 (38.1) | 3 (2.2) | 26 (19.4) | 7 (5.2) | 28 (20.9) | 23 (82.1) |
| Solid | 2636 | 351 (13.3) | 1316 (49.9) | 40 (1.5) | 574 (21.8) | 277 (10.5) | 628 (23.8) | 154 (24.5) |
| Liver cancer | 177 | 114 (64.4) | 45 (25.4) | 17 (9.6) | 114 (64.4) | 27 (15.3) | 141 (79.7) | 68 (48.2) |
| Others | 2459 | 207 (8.4) | 1271 (41.7) | 23 (0.9) | 114 (64.4) | 250 (10.2) | 487 (19.8) | 84 (3.5) |
1
HBV-sm positive: HBV serological marker positive (HBsAg positive and/or isolated HBcAb positive);
2
Percentage equals the screening number of HBV DNA/number of HBV-sm positive. HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody; HBeAg: Hepatitis B e antigen; HBeAb: Hepatitis B e antibody; HBcAb: Hepatitis B core antibody.